202 related articles for article (PubMed ID: 26680550)
21. Effect of cabergoline on metabolism in prolactinomas.
Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
[TBL] [Abstract][Full Text] [Related]
22. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
23. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.
Andereggen L; Frey J; Christ E
Endocrine; 2021 Apr; 72(1):216-222. PubMed ID: 33275185
[TBL] [Abstract][Full Text] [Related]
24. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
25. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
26. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
27. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Rastogi A; Bhadada SK; Bhansali A
Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal.
Watanabe S; Akutsu H; Takano S; Yamamoto T; Ishikawa E; Suzuki H; Matsumura A
Clin Endocrinol (Oxf); 2017 Feb; 86(2):207-213. PubMed ID: 27651307
[TBL] [Abstract][Full Text] [Related]
29. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
30. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
31. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Teixeira M; Souteiro P; Carvalho D
Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
[TBL] [Abstract][Full Text] [Related]
32. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
[TBL] [Abstract][Full Text] [Related]
33. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
Delgrange E; Daems T; Verhelst J; Abs R; Maiter D
Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
[TBL] [Abstract][Full Text] [Related]
34. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
35. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
[TBL] [Abstract][Full Text] [Related]
36. Prolactinomas, cabergoline, and pregnancy.
Glezer A; Bronstein MD
Endocrine; 2014 Sep; 47(1):64-9. PubMed ID: 24985062
[TBL] [Abstract][Full Text] [Related]
37. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
[TBL] [Abstract][Full Text] [Related]
39. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Bueno C; Trarbach EB; Bronstein MD; Glezer A
Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
[TBL] [Abstract][Full Text] [Related]
40. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]